<DOC>
	<DOCNO>NCT01644188</DOCNO>
	<brief_summary>Alirocumab ( SAR236553/REGN727 ) fully human monoclonal antibody bind PCSK9 ( proprotein convertase subtilisin/kexin type 9 ) . Primary Objective study : To demonstrate reduction low-density lipoprotein cholesterol ( LDL-C ) alirocumab add-on therapy stable maximally tolerated daily statin therapy comparison ezetimibe 24 week treatment participant hypercholesterolemia high cardiovascular ( CV ) risk . Secondary Objectives : - To evaluate effect alirocumab comparison ezetimibe LDL-C time point - To evaluate effect alirocumab lipid parameter - To evaluate safety tolerability alirocumab</brief_summary>
	<brief_title>Efficacy Safety Alirocumab ( SAR236553/REGN727 ) Versus Ezetimibe Top Statin High Cardiovascular Risk Patients With Hypercholesterolemia ( ODYSSEY COMBO II )</brief_title>
	<detailed_description>The maximum study duration 115 week per participant , include 3-week screening period , 104-week randomized treatment period 8-week follow-up period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Inclusion criterion : Participants hypercholesterolemia establish coronary heart disease ( CHD ) CHD risk equivalent adequately control maximally tolerate daily dose statin stable dose least 4 week prior screen visit ( Week 2 ) . Exclusion criterion : Age &lt; 18 legal age adulthood , whichever great Participants without establish CHD CHD risk equivalent LDLC &lt; 70 mg/dL ( &lt; 1.81 mmol/L ) participant history document cardiovascular disease LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) participant without history document CV disease Fasting serum triglyceride &gt; 400 mg/dL ( &gt; 4.52 mmol/L ) The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>